UOC
PTGX icon

UBS O'Connor’s Protagonist Therapeutics PTGX Stock Holding History

UBS O'Connor’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$7.5K – 443
2025
Q1 		$7.5K Buy
+20,000
New +$838K ﹤0.01% 311
2024
Q4 		– Sell
-40,000
Closed -$164K – 545
2024
Q3 		$164K Buy
+40,000
New +$1.62M ﹤0.01% 395

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS O'Connor's PTGX Position: Q3 2025 in Review

UBS O'Connor sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 14,523 shares — an estimated $803K sold.

UBS O'Connor first reported a position in PTGX in Q1 2022 and held it in 12 quarters. The position peaked at $3.16M in Q1 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • UBS O'Connor reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 14,523 Protagonist Therapeutics shares in Q3 2025, an estimated $803K.
  • UBS O'Connor first reported a position in Protagonist Therapeutics in Q1 2022 and held it in 12 quarters.
  • UBS O'Connor's Protagonist Therapeutics position peaked at $3.16M in Q1 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.